Experimental & Molecular Medicine 'Under Review': What the Status Means

The first status period is not the full scientific review. It is the journal checking whether the record can be handled: files open correctly, author metadata is complete, disclosures are included, ethics statements are present, and the manuscript appears to match the journal's scope. For Experimental & Molecular Medicine, this stage matters because a small administrative issue can look like a peer-review delay from the author's side. If the status changes quickly to Under Review, read that as a routing signal, not as proof that every reviewer has accepted.

The useful action during this stage is not to ask whether the editor likes the paper. It is to make sure every status email, submission-form field, and manuscript file points to the same claim. A mismatch between the cover letter, abstract, figure sequence, and supplementary files creates editorial friction even when the work is credible. For Experimental & Molecular Medicine, the file package should make clear that the manuscript ties a molecular or cellular mechanism to human-health relevance, in vivo or disease-model validity, and translational interpretation rather than only a descriptive molecular finding before a reviewer has to reconstruct the claim.

At this point the manuscript is being read for fit. The editor is not only asking whether the manuscript is polished, but whether the manuscript ties a molecular or cellular mechanism to human-health relevance, in vivo or disease-model validity, and translational interpretation rather than only a descriptive molecular finding. A manuscript can be technically careful and still difficult to route if the abstract promises one contribution while the methods, figures, data, or supplementary files support another.

The editor may be matching the manuscript to molecular-medicine editors, disease-mechanism reviewers, immunology or oncology reviewers, translational biology readers, in vivo model reviewers, and Springer Nature manuscript-tracking staff. That matching process can take time because the editor needs reviewers who can evaluate the central claim without rebuilding the manuscript's logic from scratch. Under Review can therefore cover both reviewer recruitment and active review.

At Experimental & Molecular Medicine, the handling editor is usually making two decisions at once: whether the submission deserves outside assessment and which reviewer pool can test the manuscript fairly. The handling editor is usually testing scope, article type, evidence traceability, conflicts, reviewer availability, and whether the manuscript's strongest claim is auditable. That editorial culture matters because the status label can look static while the handling editor checks disease mechanism, molecular tool, model-system rationale, human relevance, in vivo or clinical linkage, validation experiment, statistics, data availability, ethics statements, and limitation language. Authors should prepare for comments on those components while the handling editor is still shaping the review path.

In parallel, the editor may be identifying two to three reviewers and checking whether the manuscript has the right scope for those reviewers. Recruiting reviewers can take 7 to 21 days when the topic sits between fields, depends on a specialized dataset, or requires both methodological and domain expertise. A Experimental & Molecular Medicine manuscript can therefore show Under Review while the editor is still securing the right reviewer mix.

For authors, the useful question is not "has someone accepted yet?" The useful question is "if a reviewer accepts today, would the manuscript's disease mechanism, molecular tool, model-system rationale, human relevance, in vivo or clinical linkage, validation experiment, statistics, data availability, ethics statements, and limitation language make the claim easy to evaluate?" That is the difference between passive waiting and productive waiting.

This is the main period in which reviewers evaluate the paper. They are usually checking whether the conclusion follows from the methods, whether the strongest comparison or control is present, whether figures match claims, and whether limitations are honest. In Experimental & Molecular Medicine, the common weak point is not always the headline finding. It is often the missing bridge between the manuscript's strongest claim and the evidence a reviewer can audit quickly.

Active review is also where timeline anxiety becomes least informative. A quiet portal does not tell you whether one reviewer is late, whether the editor is waiting for another report, whether a reviewer declined and had to be replaced, or whether reports are already in synthesis. The strongest response is to prepare the material you will need under every plausible decision path.

Use the waiting window to produce a revision-ready response map. Put the likely objection in one column, the manuscript location in another, the strongest supporting figure or table in a third, and the limitation language in a fourth. If the decision is revise, that map saves days. If the decision is reject, it helps you choose a cleaner transfer or resubmission path.

After reports arrive, the editor has to turn them into a decision. This can still look like Under Review, Reviews Complete, Required Reviews Complete, or Decision in Process depending on the portal. Do not assume silence during this period means rejection. It can mean the editor is reconciling mixed reports, checking whether one reviewer misunderstood the scope, or deciding whether the manuscript needs another opinion.

The synthesis window is where the editor tests whether the reviewer concerns are compatible. If one reviewer wants deeper methods and another wants a shorter argument, the decision letter may take longer because the editor has to decide which instruction governs the revision. That delay is procedural, not necessarily negative.

Not automatically. The most common explanation is reviewer recruitment or a delayed report, not a hidden rejection. The more useful interpretation is whether the elapsed time matches the stage. If the paper moved to Under Review quickly and then stayed there, the editor may still be waiting on one reviewer. If the status changed after several weeks, the editor may be synthesizing reports. If there has been no movement past 10 weeks, a polite inquiry is reasonable.

What you should not do is rewrite the manuscript in panic or submit elsewhere. Prepare the response materials that will matter if the decision is revise, reject with comments, or transfer.

Across our pre-submission review work with Experimental & Molecular Medicine manuscripts, three named status-risk patterns explain most of the productive work authors can do while the portal still says Under Review. These patterns are useful because they are tied to manuscript components a reviewer can inspect, not to generic advice about waiting.

In our pre-submission review work on Experimental & Molecular Medicine manuscript packages, each specific failure pattern below turns into a concrete status-window task: inspect the abstract, first figure or model, methods, cover letter, data files, reporting notes, and limitation language before the reviewer report arrives.

The pages that create the most avoidable status anxiety are not always the obviously weak papers. They are credible papers where authors wait passively during Under Review instead of preparing for the exact review objections most likely to arrive. Official guidance explains the workflow, but it rarely connects the status label to the manuscript components reviewers will test.

• Experimental & Molecular Medicine evidence-chain gap: The editor needs to see disease mechanism, molecular tool, model-system rationale, human relevance, in vivo or clinical linkage, validation experiment, statistics, data availability, ethics statements, and limitation language without piecing together the claim from scattered files. Prepare a one-page response map that ties the central claim to figures, methods, data files, theory, and limitations.

• Experimental & Molecular Medicine reviewer-routing risk: The wrong reviewer pool can make a sound paper look less convincing than it is. Use the waiting window to identify how the abstract, keywords, suggested reviewers, article type, and field framing point to molecular-medicine editors, disease-mechanism reviewers, immunology or oncology reviewers, translational biology readers, in vivo model reviewers, and Springer Nature manuscript-tracking staff.

• Experimental & Molecular Medicine source-to-claim friction: Reviewers move quickly from headline claim to evidence traceability. Check that source data, repository links, supplementary files, figure legends, models, theory logic, and methods are easy to audit.

• Experimental & Molecular Medicine revision-readiness gap: Revision speed depends on whether authors already know which objection is likely. Draft answer blocks for the two most likely reviewer concerns before the decision letter arrives.

The recurring Manusights pattern is that authors often over-prepare the wrong asset while the manuscript is under review. They polish prose when the likely reviewer objection is a missing control, rewrite the introduction when the likely problem is a benchmark table, or wait for the decision letter when the abstract, methods, figures, theory, and supplementary files already reveal the response strategy. For Experimental & Molecular Medicine, the highest-value waiting work is to make the evidence chain explicit enough that a reviewer can test the claim without inventing the authors' logic.

Of the 100 most recent Manusights pre-submission reviews we use as a status-page pattern sample, the useful signal was not the portal label by itself. It was whether the draft already had a journal-specific evidence map before reports arrived. Official guidance explains the workflow, but that is why this page ties Under Review to disease mechanism, molecular tool, model-system rationale, human relevance, in vivo or clinical linkage, validation experiment, statistics, data availability, ethics statements, and limitation language instead of only defining the status phrase.

If you want a second set of eyes before the report lands, use the Experimental & Molecular Medicine AI review to identify reviewer-risk issues while the manuscript is still under review.

JCI Insight, Molecular Therapy, Cell Death & Disease, Communications Biology, Nature Communications, and specialist disease journals can be better routes when the manuscript is more clinical, more mechanistic, or narrower than Experimental & Molecular Medicine expects. Do not treat transfer planning as pessimism. It is a way to shorten the next move if the decision letter confirms the current venue is one level too broad, too narrow, or too format-specific.

Source limitations: this page uses public official-source guidance plus Manusights manuscript-risk interpretation; it cannot see the private reviewer invitations, report status, or handling-editor notes inside your manuscript record.

Public journal guidance can tell you the portal, article-scope language, submission route, and broad peer-review policy. It usually cannot tell you whether your specific paper has reviewers assigned, whether a reviewer has missed a deadline, or whether the editor is leaning toward revision or rejection. That is why this page separates official-source facts from practical interpretation. The official sources anchor the workflow; the Manusights contribution is the manuscript-level risk translation.

Official sources used for this Under Review interpretation:

• https://www.nature.com/emm
• https://www.nature.com/emm/journal-information
• https://www.nature.com/emm/for-authors
• https://mts-emm.nature.com/cgi-bin/main.plex?form_type=home
• https://support.nature.com/en/support/solutions/articles/6000228447-find-submission-status-of-your-article-manuscript

Source-specific notes from this research pass:

• Nature journal information says Experimental & Molecular Medicine highlights clinical benefits from experimental and translational research using specific molecular tools.
• The EMM manuscript-tracking page identifies the official online manuscript submission and tracking system.
• Nature Support says authors can track submitted manuscripts through Your research and follow action-required steps from the manuscript record.

• Experimental & Molecular Medicine hub
• Experimental & Molecular Medicine submission guide
• Experimental & Molecular Medicine impact factor
• how to avoid desk rejection at Experimental & Molecular Medicine
• JCI submission guide
• Nature Medicine submission guide
• not-ready warning signs
• cover-letter guide

Before you wait another month, run a Experimental & Molecular Medicine reviewer-risk check and prepare the revision map reviewers are most likely to force you to build later.